Pravan SuntharasamaiD. A. WarrellSornchai LooareesuwanM. J. WarrellChaisin ViravanWichai SupanaranondPornthep ChanthavanichAchara SupapochanaWeera TepsumethanonX. Pouradier-DuteilMahidol UniversityNuffield Department of Clinical MedicineThai Red Cross AgencyInstitut Merieux2018-02-272018-02-271986-07-19The Lancet. Vol.328, No.8499 (1986), 129-131014067362-s2.0-0022655203https://repository.li.mahidol.ac.th/handle/20.500.14594/9807The protective effect of a new, potentially economical tissue-culture rabies vaccine, purified vero-cell rabies vaccine (PVRV), was tested in 106 patients bitten by animals with proven rabies. 0·5 ml PVRV was given intramuscularly on days 0, 3, 7, 14, 28, and 91; 47 patients with severe exposure were also given 20 IU/kg human rabies immune globulin (HRIG). All patients are alive and well after 1 year. Side-effects of treatment were negligible. Rabies neutralising antibody (≥ 1·6 IU) was demonstrated on day 14 and persisted for 1 year in every case. There was no significant suppression of the antibody response by HRIG. If the untreated mortality is 15%, PVRV is 81% efficient in protecting patients against rabies encephalitis (95% confidence limit). PVRV is likely to replace human diploid-cell strain vaccine as the most widely used tissue-culture rabies vaccine. © 1986.Mahidol UniversityMedicineArticleSCOPUS10.1016/S0140-6736(86)91946-X